CA2230777C - Advanced synchronous luminescence system - Google Patents
Advanced synchronous luminescence system Download PDFInfo
- Publication number
- CA2230777C CA2230777C CA002230777A CA2230777A CA2230777C CA 2230777 C CA2230777 C CA 2230777C CA 002230777 A CA002230777 A CA 002230777A CA 2230777 A CA2230777 A CA 2230777A CA 2230777 C CA2230777 C CA 2230777C
- Authority
- CA
- Canada
- Prior art keywords
- excitation
- tissue sample
- radiation
- emission
- filter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000001360 synchronised effect Effects 0.000 title claims abstract description 45
- 238000004020 luminiscence type Methods 0.000 title abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 33
- 238000001228 spectrum Methods 0.000 claims abstract description 33
- 230000005284 excitation Effects 0.000 claims description 78
- 230000005855 radiation Effects 0.000 claims description 77
- 239000000523 sample Substances 0.000 claims description 61
- 239000000975 dye Substances 0.000 claims description 43
- 239000013307 optical fiber Substances 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 7
- 230000003211 malignant effect Effects 0.000 claims description 5
- 238000010998 test method Methods 0.000 claims description 5
- 230000005856 abnormality Effects 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 abstract description 15
- 210000001519 tissue Anatomy 0.000 description 31
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 17
- 230000003595 spectral effect Effects 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 208000037062 Polyps Diseases 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000013078 crystal Substances 0.000 description 9
- 239000000835 fiber Substances 0.000 description 9
- 239000010453 quartz Substances 0.000 description 8
- 239000000990 laser dye Substances 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 3
- UIZLQMLDSWKZGC-UHFFFAOYSA-N cadmium helium Chemical compound [He].[Cd] UIZLQMLDSWKZGC-UHFFFAOYSA-N 0.000 description 3
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 3
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 3
- 208000017819 hyperplastic polyp Diseases 0.000 description 3
- 238000001748 luminescence spectrum Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000006098 acoustic absorber Substances 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 210000004953 colonic tissue Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 229910052724 xenon Inorganic materials 0.000 description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- XBDYBAVJXHJMNQ-UHFFFAOYSA-N Tetrahydroanthracene Natural products C1=CC=C2C=C(CCCC3)C3=CC2=C1 XBDYBAVJXHJMNQ-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- MUJOIMFVNIBMKC-UHFFFAOYSA-N fludioxonil Chemical compound C=12OC(F)(F)OC2=CC=CC=1C1=CNC=C1C#N MUJOIMFVNIBMKC-UHFFFAOYSA-N 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- IFLREYGFSNHWGE-UHFFFAOYSA-N tetracene Chemical compound C1=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C21 IFLREYGFSNHWGE-UHFFFAOYSA-N 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6402—Atomic fluorescence; Laser induced fluorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/12—Generating the spectrum; Monochromators
- G01J3/1256—Generating the spectrum; Monochromators using acousto-optic tunable filter
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6456—Spatial resolved fluorescence measurements; Imaging
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Non-Portable Lighting Devices Or Systems Thereof (AREA)
Abstract
A method and apparatus for determining the condition of tissue or otherwise making chemical identifications includes exposing the sample to a light sour ce (22), and using a synchronous luminescence system (38, 50) to produce a spectrum that can be analyzed for tissue condition.
Description
ADVANCED SYNCHRONOUS LUMINESCENCE SYSTEM
FIELD OF THE INVENTION
The present invention relates generally to the fields of chemical analysis and biomedical 5 diagnostics, and more specifically, to the use of synchronous luminescence to perform biomedical diagnostics. A multi-dye laser source, or a light source coupled to an acousto-optic tunable filter is used to induce from a 10 sample luminescence having a unique spectral signature.
BACKGROUND OF THE INVENTION
Laser-induced fluorescence (LIF) has been investigated recently as a method to 15 discriminate tumors from normal tissues. LIF
techniques have also been used to characterize pre-malignant colorectal lesions and to distinguish adenomatone polyps from normal colon tissue and hyperplastic polyps.
Others have investigated the use of LIF to distinguish adenomatous tissue from normal colon tissue in vivo. In these investigations, a laser such as a pulsed nitrogen laser-pumped dye 5 laser system (370 nm) was used as the excitation source. The sensitivity, specificity and predictive value for diagnostics of their technique towards adenomas were reported to be very good. Because only a small number of 10 hyperplastic polyps were examined, it is unclear whether colonic neoplasia can be reliably identified, since it is not known whether the observed differences in fluorescence arise from compositional changes specific to dysplasia or 15 simply from structural differences between polyps and the colon.
The LIF technique has also been used to distinguish adenomatous from normal colon tissue in vitro. In a study conducted by Kapalia et 20 al. in 1990, endoscopically resected polyps were excited using a continuous wave (cw) helium-cadmium laser (325 nm) and the resulting fluorescence of these endoscopically resected polyps was measured with an optical-25 multichannel-analyzer system. They found that adenomatous polyps (51 of 51) could be reliably distinguished from normal colonic tissue (69 of 69) in vitro based on LIF scores from a stepwise multivariate linear regression (MVLR) analysis 30 of their data. In addition, 15 of 16 hyperplastic polyps fell within the normal colonic tissue range, resulting in the ability to distinguish colonic neoplasia of resected tissue.
FIELD OF THE INVENTION
The present invention relates generally to the fields of chemical analysis and biomedical 5 diagnostics, and more specifically, to the use of synchronous luminescence to perform biomedical diagnostics. A multi-dye laser source, or a light source coupled to an acousto-optic tunable filter is used to induce from a 10 sample luminescence having a unique spectral signature.
BACKGROUND OF THE INVENTION
Laser-induced fluorescence (LIF) has been investigated recently as a method to 15 discriminate tumors from normal tissues. LIF
techniques have also been used to characterize pre-malignant colorectal lesions and to distinguish adenomatone polyps from normal colon tissue and hyperplastic polyps.
Others have investigated the use of LIF to distinguish adenomatous tissue from normal colon tissue in vivo. In these investigations, a laser such as a pulsed nitrogen laser-pumped dye 5 laser system (370 nm) was used as the excitation source. The sensitivity, specificity and predictive value for diagnostics of their technique towards adenomas were reported to be very good. Because only a small number of 10 hyperplastic polyps were examined, it is unclear whether colonic neoplasia can be reliably identified, since it is not known whether the observed differences in fluorescence arise from compositional changes specific to dysplasia or 15 simply from structural differences between polyps and the colon.
The LIF technique has also been used to distinguish adenomatous from normal colon tissue in vitro. In a study conducted by Kapalia et 20 al. in 1990, endoscopically resected polyps were excited using a continuous wave (cw) helium-cadmium laser (325 nm) and the resulting fluorescence of these endoscopically resected polyps was measured with an optical-25 multichannel-analyzer system. They found that adenomatous polyps (51 of 51) could be reliably distinguished from normal colonic tissue (69 of 69) in vitro based on LIF scores from a stepwise multivariate linear regression (MVLR) analysis 30 of their data. In addition, 15 of 16 hyperplastic polyps fell within the normal colonic tissue range, resulting in the ability to distinguish colonic neoplasia of resected tissue.
WO 96!07889 PCTlUS95/11168 Schomacker et al., in 1992, also used a MVLR analysis method to distinguish neoplastic tissue from non-neoplastic tissue. Their data suggested that the LIF measurements sense changes in polyp morphology rather than changes in fluorplores specific to polyps, and it was this change in morphology that leads indirectly to discrimination of polyps. Schomacker concluded that the feasibility of discriminating groups of normal from dysplastic cells by LIF
had not yet been demonstrated.
The above examples underscore the fact that, in spite of some specific successes, one of the major limitations of the LIF technique is its specificity. The laser used as the excitation source used under current conditions can yield high intensity but does not provide a selective tool for excitation.
Tissue fluorescence is a complex process arising from the superposition of the fluorescence of many chemical species in tissue.
Although changes in fluorescence profiles have been reported by many researchers involved, these changes are often difficult to provide unique "spectral signatures" useful-for unequivocal diagnostic purposes.
In addition to spectral specificity problems, current instrumentation for cancer diagnostics have serious limitations. A laser-based LIF instrument can use only fixed excitation whereas conventional spectrometers (non-laser devices) do not provide rapid synchronous luminescence (SL) scanning capabilities for useful clinical applications.
had not yet been demonstrated.
The above examples underscore the fact that, in spite of some specific successes, one of the major limitations of the LIF technique is its specificity. The laser used as the excitation source used under current conditions can yield high intensity but does not provide a selective tool for excitation.
Tissue fluorescence is a complex process arising from the superposition of the fluorescence of many chemical species in tissue.
Although changes in fluorescence profiles have been reported by many researchers involved, these changes are often difficult to provide unique "spectral signatures" useful-for unequivocal diagnostic purposes.
In addition to spectral specificity problems, current instrumentation for cancer diagnostics have serious limitations. A laser-based LIF instrument can use only fixed excitation whereas conventional spectrometers (non-laser devices) do not provide rapid synchronous luminescence (SL) scanning capabilities for useful clinical applications.
There is, therefore, a strong need to develop new or improved methods and instrumentation for sensitive as well as selective chemical analysis and biomedical 5 diagnostics.
~ttNrHrA~y OF THE INVENTION
An object of the present invention is to provide a method and apparatus which utilizes synchronous luminescence to render medical 10 diagnoses.
Another object of the present invention is to provide a method and apparatus capable of making chemical identifications and/or medical diagnoses with relative speed, improved accuracy 15 and efficiency, thereby leading to significant advances in the understanding of cancer therapy in general and the effective detection of tumors, for example.
These and other objects of the invention 20 are met by providing a method of testing a tissue sample which includes the steps of exposing the tissue sample to an excitation radiation and thereby generating an emission radiation, synchronously scanning the wavelength 25 of the excitation radiation and the wavelength of the emission radiation to produce a spectrum, and correlating the spectrum to a condition of the tissue sample.
Other objects, advantages and salient 30 features of the invention will become apparent from the following detailed description, which, taken in conjunction with the annexed drawings, WO 96107889 PCTlt1S95111168 discloses preferred embodiments of the invention.
Figure 1 is a composite graph showing fluorescence spectra of individual components of tissue, using conventional (i.e., fixed excitation) laser-induced fluorescence and using laser-induced synchronous luminescence of the present invention;
1~ F;pure 2 is a schematic view of a first preferred embodiment of an instrument capable of making chemical and biomedical identifications according to the present invention;
Figure 3 is a schematic view of a laser dye unit capable of use in the instrument of Figure 2;
Figure 4 is a schematic view of an alternative laser dye unit;
Figure 5 is a schematic view of another alternative laser dye unit;
Figure 6 is a schematic view of another preferred embodiment of an instrument for making chemical and biomedical identifications according to the present invention;
Figure 7 is a schematic view of another preferred embodiment of an instrument for making chemical and biomedical identifications according to the present invention;
Figure 8 is a schematic view of another preferred embodiment of an instrument for making chemical and biomedical identifications according to the present invention;
~ttNrHrA~y OF THE INVENTION
An object of the present invention is to provide a method and apparatus which utilizes synchronous luminescence to render medical 10 diagnoses.
Another object of the present invention is to provide a method and apparatus capable of making chemical identifications and/or medical diagnoses with relative speed, improved accuracy 15 and efficiency, thereby leading to significant advances in the understanding of cancer therapy in general and the effective detection of tumors, for example.
These and other objects of the invention 20 are met by providing a method of testing a tissue sample which includes the steps of exposing the tissue sample to an excitation radiation and thereby generating an emission radiation, synchronously scanning the wavelength 25 of the excitation radiation and the wavelength of the emission radiation to produce a spectrum, and correlating the spectrum to a condition of the tissue sample.
Other objects, advantages and salient 30 features of the invention will become apparent from the following detailed description, which, taken in conjunction with the annexed drawings, WO 96107889 PCTlt1S95111168 discloses preferred embodiments of the invention.
Figure 1 is a composite graph showing fluorescence spectra of individual components of tissue, using conventional (i.e., fixed excitation) laser-induced fluorescence and using laser-induced synchronous luminescence of the present invention;
1~ F;pure 2 is a schematic view of a first preferred embodiment of an instrument capable of making chemical and biomedical identifications according to the present invention;
Figure 3 is a schematic view of a laser dye unit capable of use in the instrument of Figure 2;
Figure 4 is a schematic view of an alternative laser dye unit;
Figure 5 is a schematic view of another alternative laser dye unit;
Figure 6 is a schematic view of another preferred embodiment of an instrument for making chemical and biomedical identifications according to the present invention;
Figure 7 is a schematic view of another preferred embodiment of an instrument for making chemical and biomedical identifications according to the present invention;
Figure 8 is a schematic view of another preferred embodiment of an instrument for making chemical and biomedical identifications according to the present invention;
Figure 9 is a schematic view of another preferred embodiment of an instrument for making chemical and biomedical identifications according to the present invention;
5 Figure 10 is a schematic view of another preferred embodiment of an instrument for making chemical and biomedical identifications according to the present invention;
Figure 11 is a display showing examples of 10 synchronous luminescence of various types of tissues;
Figure 12 is a schematic view of another preferred embodiment of an instrument for making chemical and biomedical identifications 15 according to the present invention;
Figure 13 is a schematic view of another preferred embodiment of an instrument for making chemical and biomedical identifications according to the present invention; and 20 Figure 14 is a schematic view of another preferred embodiment of an instrument for making chemical and biomedical identifications according to the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
25 The present invention combines the high intensity of a laser at the excitation source with the improved selectivity of the synchronous luminescence (SL} technique to perform chemical and biomedical diagnostics. The general theory 30 of the SL method has been described previously in "Synchronous Excitation Spectroscopy," by T.
Vo-Dinh, Modern Fluorescence ~~ectroscopv, Chapter 5, Ed. by E.L. Wehry (Plenum Publ. Corp.
5 Figure 10 is a schematic view of another preferred embodiment of an instrument for making chemical and biomedical identifications according to the present invention;
Figure 11 is a display showing examples of 10 synchronous luminescence of various types of tissues;
Figure 12 is a schematic view of another preferred embodiment of an instrument for making chemical and biomedical identifications 15 according to the present invention;
Figure 13 is a schematic view of another preferred embodiment of an instrument for making chemical and biomedical identifications according to the present invention; and 20 Figure 14 is a schematic view of another preferred embodiment of an instrument for making chemical and biomedical identifications according to the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
25 The present invention combines the high intensity of a laser at the excitation source with the improved selectivity of the synchronous luminescence (SL} technique to perform chemical and biomedical diagnostics. The general theory 30 of the SL method has been described previously in "Synchronous Excitation Spectroscopy," by T.
Vo-Dinh, Modern Fluorescence ~~ectroscopv, Chapter 5, Ed. by E.L. Wehry (Plenum Publ. Corp.
(1981) .
The principle of the synchronous luminescence approach for diagnostics of normal 5 and cancer tissues is illustrated in Figure 1.
One of the problems of fluorescence technique as it is used currently is the fixed wavelength excitation source (e. g., a laser).
Fluorescence from tissues originate from to many biological components (e. g., NADH, porphyrins, etc.). Each component has specific absorption and emission spectra occurring at determined spectral ranges, as seen in section "A" of Figure 1. The spectra illustrated in A
15 are as follows:
a = tryptophan b = collagen c = NADH
d = FAD
20 a = porphyrin Thus, each curve of A represents the fluorescence of individual components in tissues which might be sampled for the presence of an abnormality, such as a malignancy. ("NADH"
25 stands for nicotinamide adenine dinucleotide, and "FAD" stands for Flavin adenine dinucleotide) In conventional laser-induced fluorescence (LIF), the laser excitation emission line is fixed (e.g., 337 nm for the nitrogen laser; 325 30 nm for the helium-cadmium laser). When a fixed laser line is used it is difficult, if not WO 96/07889 PCTlUS95/11168 impossible, to excite all the biological components under optimal conditions. Another important limitation of conventional LIF is due to the fact that the fluorescence from tissues 5 arises from the emission of different species, resulting in spectra that are poorly resolved and featureless because of spectral overlap between the emissions from individual components, as seen in the "B" section of Figure 10 1. The laser used in LIF can only improve the sensitivity but does not enhance the selectivity.
With the present synchronous luminescence technique, both ~~ and ~~ are scanned 15 synchronously with a constant interval between the two wavelengths (G1~ _ ~~ - ~~). Since the synchronous luminescence spectrum of each component becomes sharper due to the band-narrowing effect of the synchronous luminescence 20 technique, the resulting fluorescence spectrum of the tissues sampled becomes more resolved with sharp peaks that are readily identified.
These can be seen in section "C" of Figure 1 as peaks a', b', c', d', and e'.
25 The present use of laser-induced synchronous luminescence (LISL) can provide a better spectral signature of tumors and normal tissues. Many subtle spectral features that are indiscernible in conventional LIF spectra can be revealed in the present LISL technique.
An instrument 20 capable of effecting LISL
technique is shown schematically in Figure 2.
The instrument includes a laser 22 outputting a beam 24 having a given wavelength. The laser 20 could be a portable pulsed nitrogen laser, for example.
The output beam 24 is coupled to means 26 for changing the wavelength of the output beam 24. In the illustrated embodiment of Figure 2, the means is a multi-dye module (MDM) 26. The output of the MDM 26 is delivered, through a focusing lens 28, to an optical fiber (or fibers) 30. The optical fiber 30 can be a single fiber of, for example, 600-~cm diameter quartz optical fiber, or multi-fiber bundle could be employed. This fiber or fibers transmits the excitation radiation to the sample being investigated.
The optical fiber 30 transmits the output beam to a probe 32 juxtaposed a sample 34. The probe 32 can~be inserted into the working channels of an endoscope for in vivo measurements.
An optical fiber (or fibers) 36 transmits the fluorescence of the sample 34 to detector 5 means 38. The detector means 38 includes a monochromator (MON) 40 and a photomultiplier (PM) 42. A boxcar integrator (BCI) 44, synchronized with the laser pulse via a pulse generator (PG) 46 acting as a trigger is used to 10 record and process the fluorescence signal. A
synchronous scanning device (SC) 48 ensures that the excitation radiation (~~) and the emission radiation (~~) are maintained at a constant interval (~). A portable computer 50, or other 15 suitable data collection, analysis and/or display devices, can be used to generate the synchronous luminescence spectra such as that which is illustrated in the C section of Figure 1.
20 Testing can also be performed to confirm the presence of certain chemicals in the sample 34. In one experiment, a prototype of the instrument 20 was able to detect 680 zeptomoles (10'21 moles) of tetracene.
25 A diagnosis of the sample 34 can be made by comparing the spectra of the sample to spectra WO 96/07889 PC'T1U595/11168 for healthy tissue samples, for example.
Further programming of the computer 50 could render comparison and diagnoses automatic by computer-assisted comparison of test spectra to pre-recorded or baseline spectra.
The MDM 26 can be any device capable of producing a suitable range of wavelengths for the scanning of ~~_. One example is shown in Figure 3, wherein a laser dye unit 52 includes three dye cells A, B and C, each containing a dye capable of producing a range of excitation wavelengths. For example, if the laser source is a nitrogen pump laser of 337 nm, the dye in cell A could be chosen to produce a range of wavelengths from 350-390 nm. The dye in cell B
could be chosen to produce a 390-420 nm range, and the dye in cell C could be chosen to produce a 420-450 nm range. The dye cells are mounted in a quartz cuvette, through which the pump laser output passes. Springs on opposite sides of the dye cells help position the cells in the optical path of the pump laser. A motor of the synchronous scanning system 48 changes the dye cells and adjusts the grating of the dye system according to the desired scanning program.
The principle of the synchronous luminescence approach for diagnostics of normal 5 and cancer tissues is illustrated in Figure 1.
One of the problems of fluorescence technique as it is used currently is the fixed wavelength excitation source (e. g., a laser).
Fluorescence from tissues originate from to many biological components (e. g., NADH, porphyrins, etc.). Each component has specific absorption and emission spectra occurring at determined spectral ranges, as seen in section "A" of Figure 1. The spectra illustrated in A
15 are as follows:
a = tryptophan b = collagen c = NADH
d = FAD
20 a = porphyrin Thus, each curve of A represents the fluorescence of individual components in tissues which might be sampled for the presence of an abnormality, such as a malignancy. ("NADH"
25 stands for nicotinamide adenine dinucleotide, and "FAD" stands for Flavin adenine dinucleotide) In conventional laser-induced fluorescence (LIF), the laser excitation emission line is fixed (e.g., 337 nm for the nitrogen laser; 325 30 nm for the helium-cadmium laser). When a fixed laser line is used it is difficult, if not WO 96/07889 PCTlUS95/11168 impossible, to excite all the biological components under optimal conditions. Another important limitation of conventional LIF is due to the fact that the fluorescence from tissues 5 arises from the emission of different species, resulting in spectra that are poorly resolved and featureless because of spectral overlap between the emissions from individual components, as seen in the "B" section of Figure 10 1. The laser used in LIF can only improve the sensitivity but does not enhance the selectivity.
With the present synchronous luminescence technique, both ~~ and ~~ are scanned 15 synchronously with a constant interval between the two wavelengths (G1~ _ ~~ - ~~). Since the synchronous luminescence spectrum of each component becomes sharper due to the band-narrowing effect of the synchronous luminescence 20 technique, the resulting fluorescence spectrum of the tissues sampled becomes more resolved with sharp peaks that are readily identified.
These can be seen in section "C" of Figure 1 as peaks a', b', c', d', and e'.
25 The present use of laser-induced synchronous luminescence (LISL) can provide a better spectral signature of tumors and normal tissues. Many subtle spectral features that are indiscernible in conventional LIF spectra can be revealed in the present LISL technique.
An instrument 20 capable of effecting LISL
technique is shown schematically in Figure 2.
The instrument includes a laser 22 outputting a beam 24 having a given wavelength. The laser 20 could be a portable pulsed nitrogen laser, for example.
The output beam 24 is coupled to means 26 for changing the wavelength of the output beam 24. In the illustrated embodiment of Figure 2, the means is a multi-dye module (MDM) 26. The output of the MDM 26 is delivered, through a focusing lens 28, to an optical fiber (or fibers) 30. The optical fiber 30 can be a single fiber of, for example, 600-~cm diameter quartz optical fiber, or multi-fiber bundle could be employed. This fiber or fibers transmits the excitation radiation to the sample being investigated.
The optical fiber 30 transmits the output beam to a probe 32 juxtaposed a sample 34. The probe 32 can~be inserted into the working channels of an endoscope for in vivo measurements.
An optical fiber (or fibers) 36 transmits the fluorescence of the sample 34 to detector 5 means 38. The detector means 38 includes a monochromator (MON) 40 and a photomultiplier (PM) 42. A boxcar integrator (BCI) 44, synchronized with the laser pulse via a pulse generator (PG) 46 acting as a trigger is used to 10 record and process the fluorescence signal. A
synchronous scanning device (SC) 48 ensures that the excitation radiation (~~) and the emission radiation (~~) are maintained at a constant interval (~). A portable computer 50, or other 15 suitable data collection, analysis and/or display devices, can be used to generate the synchronous luminescence spectra such as that which is illustrated in the C section of Figure 1.
20 Testing can also be performed to confirm the presence of certain chemicals in the sample 34. In one experiment, a prototype of the instrument 20 was able to detect 680 zeptomoles (10'21 moles) of tetracene.
25 A diagnosis of the sample 34 can be made by comparing the spectra of the sample to spectra WO 96/07889 PC'T1U595/11168 for healthy tissue samples, for example.
Further programming of the computer 50 could render comparison and diagnoses automatic by computer-assisted comparison of test spectra to pre-recorded or baseline spectra.
The MDM 26 can be any device capable of producing a suitable range of wavelengths for the scanning of ~~_. One example is shown in Figure 3, wherein a laser dye unit 52 includes three dye cells A, B and C, each containing a dye capable of producing a range of excitation wavelengths. For example, if the laser source is a nitrogen pump laser of 337 nm, the dye in cell A could be chosen to produce a range of wavelengths from 350-390 nm. The dye in cell B
could be chosen to produce a 390-420 nm range, and the dye in cell C could be chosen to produce a 420-450 nm range. The dye cells are mounted in a quartz cuvette, through which the pump laser output passes. Springs on opposite sides of the dye cells help position the cells in the optical path of the pump laser. A motor of the synchronous scanning system 48 changes the dye cells and adjusts the grating of the dye system according to the desired scanning program.
WO 96107889 PC'TIUS95111168 An alternative embodiment of a laser dye unit 54 is shown in Figure 4. The unit 54 includes a fiber optic multiplexer (MP) 56 which delivers the pump laser output to one of the 5 three dye cells A, B, and C through respective optical fibers 58, 60 and 62.
A further alternative embodiment of a laser dye unit 64 is shown in Figure 5. Dye from one of the three dye cells A, B, and C is 10 selectively delivered to a flow cell 66. Flow control valves 68 and 70 are selectively actuated to deliver dye from either of the cells A, B, and C. After use, the ctye 1s reLUrnea Lv the cells through appropriate conduits 72, 74 15 and 76. Control of the valves, and circulating pumps (not shown) can be through the computer 50 of Figure 2.
Another embodiment of an instrument 78 is illustrated in Figure 6. The instrument 78 20 includes a laser source 80 which produces a pulsed beam 82. The beam 82 passes through a multiple dye module (MDM) 84. The scanning laser excitation radiation is delivered through focusing optics 86 and an optical fiber 88 to a 25 probe 90 juxtaposed a sample 92.
A further alternative embodiment of a laser dye unit 64 is shown in Figure 5. Dye from one of the three dye cells A, B, and C is 10 selectively delivered to a flow cell 66. Flow control valves 68 and 70 are selectively actuated to deliver dye from either of the cells A, B, and C. After use, the ctye 1s reLUrnea Lv the cells through appropriate conduits 72, 74 15 and 76. Control of the valves, and circulating pumps (not shown) can be through the computer 50 of Figure 2.
Another embodiment of an instrument 78 is illustrated in Figure 6. The instrument 78 20 includes a laser source 80 which produces a pulsed beam 82. The beam 82 passes through a multiple dye module (MDM) 84. The scanning laser excitation radiation is delivered through focusing optics 86 and an optical fiber 88 to a 25 probe 90 juxtaposed a sample 92.
Emission radiation is picked up by optical fiber 94 and delivered through focusing optics 96 to a polychromator (PCH) 98 and multichannel detector (MD) 100. The multichannel detector 5 100 can be a photodiode array (PDA), charge coupled device (CCD), or other similar devices.
A synchronizing device (SD) 102 synchronizes the scanning of ~eX with data acquisition of the multichannel detector. In 10 this embodiment, the multichannel detector 100 produces a synchronous luminescence signal based on the black boxes shown in Figure 6.
This data can be collected by a personal computer which controls the synchronizing 15 device 102 and displays and/or stores the synchronous luminescence signal. At each time, tn, the excitation wavelength, ~n changes in a gradual progression. The synchronizing device 102 maintains a constant interval, ~~, between 20 the emission radiation and the excitation radiation. Note that the laser 22 and the MDM
26 of Figure 2, or the laser 80 and the MDM 84 of Fig. 6 can be replaced by solid state scanning laser (e. g., titanium saphire laser).
25 The instrument 104 shown in Figure 7 uses an acousto-optic tunable filter 106 (hereinafter identified as AOTF or ATOF) to scan the frequency of a light source 108. The light source 108 can be either a broad-band conventional light (e. g., xenon lamp) or a Laser equipped with a dye module having a broad-band 5 output (i.e., non scanning). The ATOF 106 is an electronically tunable spectral bandpass filter which can operate from the W to the infrared regions of the optical spectrum. It operates via the interaction of light with a traveling 10 acoustic wave through an anisotropic medium. An acoustic transducer is mounted on one end of a crystal, while an acoustic absorber is mounted on the other end. The transducer converts a high-frequency rf signal, from rf source 110, of 15 a given frequency into a pressure wave which propagates laterally through the crystal at a given velocity v,.
The acoustic absorber at the opposite end of the crystal serves to eliminate acoustic 20 reflections which corrupt the primary acoustic waveform. The diffracted wavelengths are self-selected within the crystal to satisfy the momentum conservation between the incident k; and the diffracted kd photon wave vectors and the 25 acoustic wave vector k, as follows:
A synchronizing device (SD) 102 synchronizes the scanning of ~eX with data acquisition of the multichannel detector. In 10 this embodiment, the multichannel detector 100 produces a synchronous luminescence signal based on the black boxes shown in Figure 6.
This data can be collected by a personal computer which controls the synchronizing 15 device 102 and displays and/or stores the synchronous luminescence signal. At each time, tn, the excitation wavelength, ~n changes in a gradual progression. The synchronizing device 102 maintains a constant interval, ~~, between 20 the emission radiation and the excitation radiation. Note that the laser 22 and the MDM
26 of Figure 2, or the laser 80 and the MDM 84 of Fig. 6 can be replaced by solid state scanning laser (e. g., titanium saphire laser).
25 The instrument 104 shown in Figure 7 uses an acousto-optic tunable filter 106 (hereinafter identified as AOTF or ATOF) to scan the frequency of a light source 108. The light source 108 can be either a broad-band conventional light (e. g., xenon lamp) or a Laser equipped with a dye module having a broad-band 5 output (i.e., non scanning). The ATOF 106 is an electronically tunable spectral bandpass filter which can operate from the W to the infrared regions of the optical spectrum. It operates via the interaction of light with a traveling 10 acoustic wave through an anisotropic medium. An acoustic transducer is mounted on one end of a crystal, while an acoustic absorber is mounted on the other end. The transducer converts a high-frequency rf signal, from rf source 110, of 15 a given frequency into a pressure wave which propagates laterally through the crystal at a given velocity v,.
The acoustic absorber at the opposite end of the crystal serves to eliminate acoustic 20 reflections which corrupt the primary acoustic waveform. The diffracted wavelengths are self-selected within the crystal to satisfy the momentum conservation between the incident k; and the diffracted kd photon wave vectors and the 25 acoustic wave vector k, as follows:
ka = k; ~ k, One can achieve optical tuning by changing the rf frequency f, which is related to ~ as follows:
s v.(n~ - no) a/f.
where n~ and no are the refractive indices of the extraordinary and ordinary wave, respectively, and a is a parameter depending upon the design of the AOTF.
The acoustic wave may be considered as the means for generating a transmission grating within the optical crystal. Instead of varying the angle of the incident beam, as would be the case for a normal diffraction grating in order to achieve wavelength selectivity, one varies the frequency of the electrical drive signal, allowing light of different wavelengths to be diffracted at the same angle. Hence with a fixed orientation of the crystal and the use of an rf generator, a tunable optical-source is readily created from a broad-band source 108.
As seen in Figure 7, the output of the ATOF
106 is the excitation radiation (~u) which is delivered to a probe 112 through an optical fiber 114. Emission radiation (1~) is delivered to a second.ATOF 116 through optical fiber 118.
Two rf signals are generated for excitation (~~x) and emission (~~ _ ~~x + ~) scanning. The output of the emission ATOF is delivered to a photodetector or a suitable multichannel 5 detector (MD) 120, such as a CCD or PDA for spectral imaging.
A variation of the Figure 7 embodiment can be seen in Figure 8, wherein an instrument 122 includes a single ATOF 124 provides means for 10 scanning the frequency of the excitation radiation (~~) delivered to a probe 126.
bmission radiation (~,~) is fed back through the ATOF 124 at an appropriate angle 8 relative to the excitation path passing through the crystal 15 of the ATOF 124. The crystal in the ATOF is made of Te02, or other material of suitable properties. The angle 8 is chosen so that + ~. Thus, in the embodiment of Figure 8, the ATOF 124 is used both for excitation and 20 emission. By selecting different angles of diffraction for emission and excitation, one can select ~, for excitation (related to rf,) and ~~ + ~ for emission using a different diffraction angle for emission. As in the 25 Figure 7 embodiment, a single-channel detector WO 96!07889 PCTIUS95I11168 or a multichannel detector (MD) 128 is used to receive the emission signal.
In the embodiment of Figure 9, the instrument 130 also uses a single ATOF 132 which scans the wavelength of the light source 134.
The rf source sends two rf signals alternately into the ATOF 132. By chopping and gated detection, the ATOF 132 can transmit excitation and emission radiation alternatively. As in the previous embodiments, a probe 136 can be juxtaposed any test sample of interest, and the emission radiation is detected With a multichannel detector 138, such as a CCD.
In the embodiment of Figure 10, the instrument 140 uses a single ATOF 142 having a rf source which provides two simultaneous outputs rf, and rf=. The rf1 signal produces an excitation radiation (~~), and rf2 produces the emission radiation(~2 = ~I + ~). A light source 144 and MD 146 are provided as in the previous embodiments. The intensity of the diffracted beam is controlled by varying the amplitude or the amount of rf power applied to the crystal of the ATOF 142. This approach can also be used to rapidly modulate, or chop the filtered source for lock-in detection schemes.
s v.(n~ - no) a/f.
where n~ and no are the refractive indices of the extraordinary and ordinary wave, respectively, and a is a parameter depending upon the design of the AOTF.
The acoustic wave may be considered as the means for generating a transmission grating within the optical crystal. Instead of varying the angle of the incident beam, as would be the case for a normal diffraction grating in order to achieve wavelength selectivity, one varies the frequency of the electrical drive signal, allowing light of different wavelengths to be diffracted at the same angle. Hence with a fixed orientation of the crystal and the use of an rf generator, a tunable optical-source is readily created from a broad-band source 108.
As seen in Figure 7, the output of the ATOF
106 is the excitation radiation (~u) which is delivered to a probe 112 through an optical fiber 114. Emission radiation (1~) is delivered to a second.ATOF 116 through optical fiber 118.
Two rf signals are generated for excitation (~~x) and emission (~~ _ ~~x + ~) scanning. The output of the emission ATOF is delivered to a photodetector or a suitable multichannel 5 detector (MD) 120, such as a CCD or PDA for spectral imaging.
A variation of the Figure 7 embodiment can be seen in Figure 8, wherein an instrument 122 includes a single ATOF 124 provides means for 10 scanning the frequency of the excitation radiation (~~) delivered to a probe 126.
bmission radiation (~,~) is fed back through the ATOF 124 at an appropriate angle 8 relative to the excitation path passing through the crystal 15 of the ATOF 124. The crystal in the ATOF is made of Te02, or other material of suitable properties. The angle 8 is chosen so that + ~. Thus, in the embodiment of Figure 8, the ATOF 124 is used both for excitation and 20 emission. By selecting different angles of diffraction for emission and excitation, one can select ~, for excitation (related to rf,) and ~~ + ~ for emission using a different diffraction angle for emission. As in the 25 Figure 7 embodiment, a single-channel detector WO 96!07889 PCTIUS95I11168 or a multichannel detector (MD) 128 is used to receive the emission signal.
In the embodiment of Figure 9, the instrument 130 also uses a single ATOF 132 which scans the wavelength of the light source 134.
The rf source sends two rf signals alternately into the ATOF 132. By chopping and gated detection, the ATOF 132 can transmit excitation and emission radiation alternatively. As in the previous embodiments, a probe 136 can be juxtaposed any test sample of interest, and the emission radiation is detected With a multichannel detector 138, such as a CCD.
In the embodiment of Figure 10, the instrument 140 uses a single ATOF 142 having a rf source which provides two simultaneous outputs rf, and rf=. The rf1 signal produces an excitation radiation (~~), and rf2 produces the emission radiation(~2 = ~I + ~). A light source 144 and MD 146 are provided as in the previous embodiments. The intensity of the diffracted beam is controlled by varying the amplitude or the amount of rf power applied to the crystal of the ATOF 142. This approach can also be used to rapidly modulate, or chop the filtered source for lock-in detection schemes.
Further variations of the ATOF embodiments include integration of the ATOF with a laser dye device, instead of gratings, for optical tuning.
Also, ATOF devices can be integrated to 5 multichannel detectors (PDA, CCD) instead of photomultiplexers in order to detect two-dimensional SL imaging spectra, as in the Figure 6 embodiment.
The present invention is effective in 10 cancer tumor diagnostics. It offers more selectivity as compared with conventional fixed-excitation laser-induced fluorescence techniques. Subtle differences in spectral signatures of normal and cancer tissues can be 15 detected more easily. The present invention combines the improved selectivity of synchronous scanning, the high intensity of laser excitation and the fast scanning of AOTF's.
The various embodiments described herein 20 can be assembled from commercially available components. For example, and referring to Figure 2, the laser 22 could be a small nitrogen/dye laser system available as models VSL-337 and VSL-DYE from Laser Science of 25 Newton, MA (USA). The monochromator 38 used to collect fluorescence radiation can be a 10-cm focal length model H-10 monochromator made by ISA of Edison, NJ (USA). The detector 42 can be a Hamamatsu Model 8760 photomultiplier.
The pulse energy of the tunable laser 5 output used in some experiments was 5-10 ~J/pulse over the range of wavelengths used in the experiments. The stepper motors used to drive both the dye module 26 and the monochromator 38 used digital (TTL) output 10 pulses from an ADC card by MetraByte Corporation of Taunton, MA (USA), model DASH-16F. The same card was used for timing and to collect the analog signai. The signal from the photomultiplier 42 is preferably amplified with 15 a fast preamplifier, such as a Stanford Research Systems Model SR445, DC-300 MHz, before being input to the boxcar integrator 44. The boxcar could be a Stanford Model SR250.
In experiments conducted using the Figure 2 20 instrument, the scan speed was 10 nm/s. The laser repetition rate was 15 Hz and the time constant at the boxcar was 0.2 s (3 pulse average). After scans, all spectra were smoothed using a second-order Savitzky-Golay 37 25 point-smoothing algorithm. Figure 11 is a display, as would be generated by a computer WO 96107889 PCT'IUS95111168 coupled to the instrument of the present invention, showing examples of synchronous luminescence spectra of various types of tissues. For the display of Figure 11, a 5 wavelength difference between excitation and emission of 10 nm was used.
The results displayed in Figure 11 indicate that it is possible to use the different spectral profiles of the synchronous 10 luminescence (SL) signal to characterize the tissues. Although the examples show results with tissue samples homogenized in solution, a similar measurement approach can also be used directly on tissue samples in vivo.
15 Normal and cancerous tissues can be better differentiated by the SL signals. It is expected that the techniques and instruments described herein can be applied to a wide variety of applications including, for example, 20 diagnosis of skin, colon, stomach, cervical cancers, etc.
The ATOF embodiments described herein also can be assembled from commercially available components. In the embodiment of Figure 12, the 25 instrument 148 includes a helium-cadmium laser 150 (Omnichrome model 3074-6) whose output is WO 96!07889 PCTIUS951111G8 directed to a silica clad-silica core optical fiber 152. The laser radiation emitted from the distal end of the optical fiber 152 is focused onto a sample 154, such as a quartz cuvette containing a sample solution, or a sample tissue) by a quartz lens 156.
The luminescence signal from the sample is collected at a right angle to the excitation beam. A pair of quartz lens 158 and 160 (f/4) are used to form a roughly collimated beam. A
Glen-Taylor (polarizing) prism 162 allows only linearly polarized light into an AOTF 164 (Hrimrose model QZAF-.25-.65). The polarization angle of the prism 162 is aligned with the polarization axis of the AOTF 164.
A second Glen-Taylor prism 166 is oriented orthogonally to the first prism 162, blocking the non-diffracted light.. A quartz lens 168 focuses the filtered light onto a photomultiplier (PM) tube 170 (Hamamatsu model 8928 ) .
The AOTF 166 can have an operating spectral range of 250-650 nm. The spectral resolution is 0.9 nm and the diffraction efficiency is 25~t at 400 nm. The. radio frequency control signal applied to the AOTF is controlled by a DOS-based computer 172 using a 16-bit computer controller board.
The signal from the PM tube 170 is converted from analog to digital and then 5 processed by the computer 172 which is programmed to control the AOTF for various scan modes. A real time data display mode can also be incorporated into the program.
In Figure 13 the laser is replaced by a 10 broad-band light source equipped with a second AOTF. Both emission and excitation AOTFs can be scanned synchronously.
The use of an optical fiber in the embodiments using one or more AOTF's can be 15 avoided. As shown in the embodiment of Figure 13, the instrument 174 includes a light source 176 and excitation radiation AOTF 178. A
surface 180 to be analyzed receives the scanning excitation radiation after passing through 20 . collimating optic 182. bnission.radiation passes through collimating optic 184 and then to emission AOTF 186, and then to a two-dimensional detector (2D) 188. These signals are then converted into spectra by a computer which 25 also controls the scanning of the two AOTFs 178 and 186. Each point of the surface has a synchronous luminescence spectrum. In this embodiment, the light source is made to illuminate the area of interest, rather than a specific point. Thus, this type of instrument can be used to diagnose large areas of sample tissues since it allows the collection of the entire synchronous luminescence spectrum of every point on the area illuminated by the light source and under the field of view of the CCD
1o detection system.
While no fiber optics were used in the Figure 13 embodiment, a coherent bundle of fibers could be used to transmit individual pixels of images in the detection process.
The embodiment of Figure 14 includes a continuum light source 190, such as a high pressure xenon lamp. The lamp output passes through a pair of quartz lenses 192, which form a roughly collimated beam. A Glen-Taylor (polarizing) prism 194 is used to allow only linearly polarized light into an AOTF 196.
The output of the AOTF 196 passes through a second prism 198 and is focused by a lens 200 to a point 202 on a tissue sample. A second pair of quartz lenses 204 form a roughly collimated beam which passes through another polarizing prism 206. Emission radiation from the sample at point 202 is thus scanned by a second AOTF
208.
Prism 210 is oriented orthogonally relative 5 to the prism 206 to block the non-diffracted light. A lens 212 is positioned to focus the filtered light onto a photomultiplier tube (PM) 214. Synchronous luminescence spectra can be produced and analyzed by coupling the output of 10 the photomultiplier to a suitable analyzer, such as a personal computer with data acquisition capabilities.
While advantageous embodiments have been chosen to illustrate the invention, it will be 15 understood by those skilled in the art that various changes and modifications can be made therein without departing from the scope of the invention as defined in the appended claims.
Also, ATOF devices can be integrated to 5 multichannel detectors (PDA, CCD) instead of photomultiplexers in order to detect two-dimensional SL imaging spectra, as in the Figure 6 embodiment.
The present invention is effective in 10 cancer tumor diagnostics. It offers more selectivity as compared with conventional fixed-excitation laser-induced fluorescence techniques. Subtle differences in spectral signatures of normal and cancer tissues can be 15 detected more easily. The present invention combines the improved selectivity of synchronous scanning, the high intensity of laser excitation and the fast scanning of AOTF's.
The various embodiments described herein 20 can be assembled from commercially available components. For example, and referring to Figure 2, the laser 22 could be a small nitrogen/dye laser system available as models VSL-337 and VSL-DYE from Laser Science of 25 Newton, MA (USA). The monochromator 38 used to collect fluorescence radiation can be a 10-cm focal length model H-10 monochromator made by ISA of Edison, NJ (USA). The detector 42 can be a Hamamatsu Model 8760 photomultiplier.
The pulse energy of the tunable laser 5 output used in some experiments was 5-10 ~J/pulse over the range of wavelengths used in the experiments. The stepper motors used to drive both the dye module 26 and the monochromator 38 used digital (TTL) output 10 pulses from an ADC card by MetraByte Corporation of Taunton, MA (USA), model DASH-16F. The same card was used for timing and to collect the analog signai. The signal from the photomultiplier 42 is preferably amplified with 15 a fast preamplifier, such as a Stanford Research Systems Model SR445, DC-300 MHz, before being input to the boxcar integrator 44. The boxcar could be a Stanford Model SR250.
In experiments conducted using the Figure 2 20 instrument, the scan speed was 10 nm/s. The laser repetition rate was 15 Hz and the time constant at the boxcar was 0.2 s (3 pulse average). After scans, all spectra were smoothed using a second-order Savitzky-Golay 37 25 point-smoothing algorithm. Figure 11 is a display, as would be generated by a computer WO 96107889 PCT'IUS95111168 coupled to the instrument of the present invention, showing examples of synchronous luminescence spectra of various types of tissues. For the display of Figure 11, a 5 wavelength difference between excitation and emission of 10 nm was used.
The results displayed in Figure 11 indicate that it is possible to use the different spectral profiles of the synchronous 10 luminescence (SL) signal to characterize the tissues. Although the examples show results with tissue samples homogenized in solution, a similar measurement approach can also be used directly on tissue samples in vivo.
15 Normal and cancerous tissues can be better differentiated by the SL signals. It is expected that the techniques and instruments described herein can be applied to a wide variety of applications including, for example, 20 diagnosis of skin, colon, stomach, cervical cancers, etc.
The ATOF embodiments described herein also can be assembled from commercially available components. In the embodiment of Figure 12, the 25 instrument 148 includes a helium-cadmium laser 150 (Omnichrome model 3074-6) whose output is WO 96!07889 PCTIUS951111G8 directed to a silica clad-silica core optical fiber 152. The laser radiation emitted from the distal end of the optical fiber 152 is focused onto a sample 154, such as a quartz cuvette containing a sample solution, or a sample tissue) by a quartz lens 156.
The luminescence signal from the sample is collected at a right angle to the excitation beam. A pair of quartz lens 158 and 160 (f/4) are used to form a roughly collimated beam. A
Glen-Taylor (polarizing) prism 162 allows only linearly polarized light into an AOTF 164 (Hrimrose model QZAF-.25-.65). The polarization angle of the prism 162 is aligned with the polarization axis of the AOTF 164.
A second Glen-Taylor prism 166 is oriented orthogonally to the first prism 162, blocking the non-diffracted light.. A quartz lens 168 focuses the filtered light onto a photomultiplier (PM) tube 170 (Hamamatsu model 8928 ) .
The AOTF 166 can have an operating spectral range of 250-650 nm. The spectral resolution is 0.9 nm and the diffraction efficiency is 25~t at 400 nm. The. radio frequency control signal applied to the AOTF is controlled by a DOS-based computer 172 using a 16-bit computer controller board.
The signal from the PM tube 170 is converted from analog to digital and then 5 processed by the computer 172 which is programmed to control the AOTF for various scan modes. A real time data display mode can also be incorporated into the program.
In Figure 13 the laser is replaced by a 10 broad-band light source equipped with a second AOTF. Both emission and excitation AOTFs can be scanned synchronously.
The use of an optical fiber in the embodiments using one or more AOTF's can be 15 avoided. As shown in the embodiment of Figure 13, the instrument 174 includes a light source 176 and excitation radiation AOTF 178. A
surface 180 to be analyzed receives the scanning excitation radiation after passing through 20 . collimating optic 182. bnission.radiation passes through collimating optic 184 and then to emission AOTF 186, and then to a two-dimensional detector (2D) 188. These signals are then converted into spectra by a computer which 25 also controls the scanning of the two AOTFs 178 and 186. Each point of the surface has a synchronous luminescence spectrum. In this embodiment, the light source is made to illuminate the area of interest, rather than a specific point. Thus, this type of instrument can be used to diagnose large areas of sample tissues since it allows the collection of the entire synchronous luminescence spectrum of every point on the area illuminated by the light source and under the field of view of the CCD
1o detection system.
While no fiber optics were used in the Figure 13 embodiment, a coherent bundle of fibers could be used to transmit individual pixels of images in the detection process.
The embodiment of Figure 14 includes a continuum light source 190, such as a high pressure xenon lamp. The lamp output passes through a pair of quartz lenses 192, which form a roughly collimated beam. A Glen-Taylor (polarizing) prism 194 is used to allow only linearly polarized light into an AOTF 196.
The output of the AOTF 196 passes through a second prism 198 and is focused by a lens 200 to a point 202 on a tissue sample. A second pair of quartz lenses 204 form a roughly collimated beam which passes through another polarizing prism 206. Emission radiation from the sample at point 202 is thus scanned by a second AOTF
208.
Prism 210 is oriented orthogonally relative 5 to the prism 206 to block the non-diffracted light. A lens 212 is positioned to focus the filtered light onto a photomultiplier tube (PM) 214. Synchronous luminescence spectra can be produced and analyzed by coupling the output of 10 the photomultiplier to a suitable analyzer, such as a personal computer with data acquisition capabilities.
While advantageous embodiments have been chosen to illustrate the invention, it will be 15 understood by those skilled in the art that various changes and modifications can be made therein without departing from the scope of the invention as defined in the appended claims.
Claims (38)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A method of testing a tissue sample to determine malignant or pre-malignant abnormality, comprising the steps of:
exposing the tissue sample to an excitation radiation and thereby generating an emission radiation;
synchronously scanning the wavelength of the excitation radiation and the wavelength of the emission radiation to produce a spectrum; and correlating the spectrum obtained from said synchronous scanning to a malignancy condition of the tissue sample.
exposing the tissue sample to an excitation radiation and thereby generating an emission radiation;
synchronously scanning the wavelength of the excitation radiation and the wavelength of the emission radiation to produce a spectrum; and correlating the spectrum obtained from said synchronous scanning to a malignancy condition of the tissue sample.
2. The method according to claim 1, wherein the exposing step comprises directing an output beam from a laser light source to the tissue sample through at least one optical fiber.
3. The method according to claim 2, further comprising directing the output of the laser light source into a probe disposed in vivo next to the tissue sample.
4. The method according to claim 1, wherein the synchronously scanning step comprises maintaining a constant interval between the wavelength of the excitation radiation and the emission radiation during synchronous scanning.
5. The method according to claim 2, wherein the scanning step further comprises directing the output beam of the laser source through a dye module having a plurality of dyes, and changing the dyes to achieve a range of excitation wavelengths.
6. The method according to claim 2, wherein the scanning step further comprises directing the output beam of the laser source through a dye container, and selectively moving a plurality of dyes into the dye container to achieve a range of excitation wavelengths.
7. The method according to claim 1, wherein the synchronous scanning step comprises directing the excitation radiation into a first acousto-optic tunable filter, and changing an input radio frequency of the first filter to achieve a range of excitation wavelengths.
8. The method according to claim 7, wherein the synchronous scanning step further comprises directing the emission radiation into a second acousto-optic tunable filter, and changing an input radio frequency of the second filter to achieve a range of emission wavelengths.
9. The method according to claim 7, wherein the synchronous scanning step further comprises directing the emission radiation into the first filter at an angle relative to the excitation radiation.
10. The method according to claim 7, wherein the synchronous scanning step further comprises directing the emission radiation into the first filter, alternately providing two radio frequency signals to the first filter to alternately pass the excitation and emission radiations through the first filter, and alternately detecting the emission radiation when the first filter is not transmitting the excitation radiation.
11. An apparatus for testing a tissue sample to determine malignant or pre-malignant abnormality, comprising:
means for exposing the tissue sample to an excitation radiation and thereby generating an emission radiation;
means for synchronously scanning the wavelength of the excitation radiation and the wavelength of the emission radiation to produce a spectrum; and means for correlating the spectrum obtained from said synchronous scanning to a malignancy condition of the tissue sample.
means for exposing the tissue sample to an excitation radiation and thereby generating an emission radiation;
means for synchronously scanning the wavelength of the excitation radiation and the wavelength of the emission radiation to produce a spectrum; and means for correlating the spectrum obtained from said synchronous scanning to a malignancy condition of the tissue sample.
12. An apparatus according to claim 11, wherein the exposing means is a laser outputting a beam and the synchronous scanning means includes a multiple dye module having a plurality of dyes, each capable of changing the wavelength of the laser beam within a specified range.
13. An apparatus according to claim 11, wherein the exposing means is a laser outputting a beam and the synchronous scanning means includes means for maintaining a constant interval between the wavelength of the excitation radiation and the emission radiation during synchronous scanning.
14. An apparatus according to claim 11, wherein the exposing means comprises a laser source outputting a beam, and the scanning means comprises means for directing the output beam of the laser source through a dye module having a plurality of dyes, and means for changing the dyes to achieve a range of excitation wavelengths.
15. An apparatus according to claim 11, wherein the exposing means comprises a light source and the scanning means includes a first acousto-optic tunable filter having a variable input radio frequency selected to achieve a range of excitation wavelengths.
16. An apparatus according to claim 15, wherein the synchronous scanning means further comprises a second acousto-optic tunable filter having a variable input radio frequency selected to achieve a range of emission wavelengths.
17. An apparatus for testing a tissue sample comprising:
a light source producing an excitation light;
a first acousto-optic tunable filter, receiving the excitation light and being operable to scan a wavelength of the excitation light within a prescribed range;
a first focusing lens, receiving and focusing the scanned excitation light onto a subject tissue sample, the subject tissue sample generating an emission light having a plurality of wavelengths;
a second acousto-optic tunable filter, receiving the emission light and being operable to scan a wavelength of the emission light within a prescribed range synchronously with the scanned excitation light; and means for detecting the synchronously scanned excitation light and emission light.
a light source producing an excitation light;
a first acousto-optic tunable filter, receiving the excitation light and being operable to scan a wavelength of the excitation light within a prescribed range;
a first focusing lens, receiving and focusing the scanned excitation light onto a subject tissue sample, the subject tissue sample generating an emission light having a plurality of wavelengths;
a second acousto-optic tunable filter, receiving the emission light and being operable to scan a wavelength of the emission light within a prescribed range synchronously with the scanned excitation light; and means for detecting the synchronously scanned excitation light and emission light.
18. An apparatus according to claim 17, further comprising first collimator means, disposed between the light source and the first filter, for producing a substantially collimated beam of light.
19. An apparatus according to claim 18, wherein the first collimator means comprises a first pair of collimating lenses.
20. An apparatus according to claim 18, further comprising first polarizing means, disposed between the first collimator means and the first filter, for allowing only linearly polarized light into the first filter.
21. An apparatus according to claim 20, wherein the first polarizing means comprises a first prism.
22. An apparatus according to claim 21, further comprising second polarizing means, disposed between the first filter and the first focusing lens, for blocking non-polarized light.
23. An apparatus according to claim 22, wherein the second polarizing means comprises a second prism oriented orthogonally to the first prism.
24. An apparatus according to claim 23, further comprising second collimator means, disposed between the first focusing lens and the second filter, for producing a substantially collimated beam of light.
25. An apparatus according to claim 24, wherein the second collimator means comprises a second pair of collimating lenses.
26. An apparatus according to claim 24, further comprising third polarizing means, disposed between the second collimator means and the second filter, for allowing only linearly polarized light into the second filter.
27. An apparatus according to claim 26, further comprising fourth polarizing means, disposed between the second filter and the detector means, for blocking non-polarized light.
28. An apparatus for testing a tissue sample comprising:
a light source for producing excitation light;
at least one acousto-optic tunable filter, said acousto-optic tunable filter disposed either between said light source and a tissue sample or between said tissue sample and a light detector;
a means for synchronously scanning said excitation light; and a first focusing lens for receiving and focusing scanned excitation light onto said tissue sample, said tissue sample generating an emission light having a plurality of wavelengths;
said light detector for detecting synchronously scanned excitation light and emission light.
a light source for producing excitation light;
at least one acousto-optic tunable filter, said acousto-optic tunable filter disposed either between said light source and a tissue sample or between said tissue sample and a light detector;
a means for synchronously scanning said excitation light; and a first focusing lens for receiving and focusing scanned excitation light onto said tissue sample, said tissue sample generating an emission light having a plurality of wavelengths;
said light detector for detecting synchronously scanned excitation light and emission light.
29. A method of testing a tissue sample comprising the steps of:
exposing the tissue sample to an excitation radiation by directing an output beam from a laser light source to the tissue sample through at least one optical fiber and thereby generating an emission radiation;
synchronously scanning the wavelength of the excitation radiation and the wavelength of the emission radiation to produce a spectrum by directing the output beam of the laser source through a dye module having a plurality of dyes, and changing the dyes to achieve a range of excitation wavelengths; and correlating the spectrum to a condition of the tissue sample.
exposing the tissue sample to an excitation radiation by directing an output beam from a laser light source to the tissue sample through at least one optical fiber and thereby generating an emission radiation;
synchronously scanning the wavelength of the excitation radiation and the wavelength of the emission radiation to produce a spectrum by directing the output beam of the laser source through a dye module having a plurality of dyes, and changing the dyes to achieve a range of excitation wavelengths; and correlating the spectrum to a condition of the tissue sample.
30. A method of testing a tissue sample comprising the steps of:
exposing the tissue sample to an excitation radiation by directing an output beam from a laser light source to the tissue sample through at least one optical fiber and thereby generating an emission radiation;
synchronously scanning the wavelength of the excitation radiation and the wavelength of the emission radiation to produce a spectrum by directing the output beam of the laser source through a dye container, and selectively moving a plurality of dyes into the dye container to achieve a range of excitation wavelengths; and correlating the spectrum to a condition of the tissue sample.
exposing the tissue sample to an excitation radiation by directing an output beam from a laser light source to the tissue sample through at least one optical fiber and thereby generating an emission radiation;
synchronously scanning the wavelength of the excitation radiation and the wavelength of the emission radiation to produce a spectrum by directing the output beam of the laser source through a dye container, and selectively moving a plurality of dyes into the dye container to achieve a range of excitation wavelengths; and correlating the spectrum to a condition of the tissue sample.
31. A method of testing a tissue sample comprising the steps of:
exposing the tissue sample to an excitation radiation and thereby generating an emission radiation;
synchronously scanning the wavelength of the excitation radiation and the wavelength of the emission radiation to produce a spectrum by directing the excitation radiation into a first acousto-optic tunable filter, and changing an input radio frequency of the first filter to achieve a range of excitation wavelenghts; and correlating the spectrum to a condition of the tissue sample.
exposing the tissue sample to an excitation radiation and thereby generating an emission radiation;
synchronously scanning the wavelength of the excitation radiation and the wavelength of the emission radiation to produce a spectrum by directing the excitation radiation into a first acousto-optic tunable filter, and changing an input radio frequency of the first filter to achieve a range of excitation wavelenghts; and correlating the spectrum to a condition of the tissue sample.
32. The method according to claim 31, wherein the synchronous scanning step further comprises directing the emission radiation into a second acousto-optic tunable filter, and changing an input radio frequency of the second filter to achieve a range of emission wavelengths.
33. The method according to claim 31, wherein the synchronous scanning step further comprises directing the emission radiation into the first filter at an angle relative to the excitation radiation.
34. The method according to claim 31, wherein the synchronous scanning step further comprises directing the emission radiation into the first filter, alternately providing two radio frequency signals to the first filter to alternately pass the excitation and emission radiations through the first filter, and alternately detecting the emission radiation when the first filter is not transmitting the excitation radiation.
35. An apparatus for testing a tissue sample comprising:
means for exposing the tissue sample to an excitation radiation and thereby generating an emission radiation, said exposing means being a laser outputting a beam;
means for synchronously scanning the wavelength of the excitation radiation and the wavelength of the emission radiation to produce a spectrum, said synchronous scanning means including a multiple dye module having a plurality of dyes, each capable of changing the wavelength of the laser beam within a specified range; and means for correlating the spectrum to a condition of the tissue sample.
means for exposing the tissue sample to an excitation radiation and thereby generating an emission radiation, said exposing means being a laser outputting a beam;
means for synchronously scanning the wavelength of the excitation radiation and the wavelength of the emission radiation to produce a spectrum, said synchronous scanning means including a multiple dye module having a plurality of dyes, each capable of changing the wavelength of the laser beam within a specified range; and means for correlating the spectrum to a condition of the tissue sample.
36. An apparatus for testing a tissue sample comprising:
means for exposing the tissue sample to an excitation radiation and thereby generating an emission radiation, said exposing means comprising a laser source outputting a beam;
means for synchronously scanning the wavelength of the excitation radiation and the wavelength of the emission radiation to produce a spectrum, said synchronous scanning means comprising means for directing the output beam of the laser source through a dye module having a plurality of dyes, and means for changing the dyes to achieve a range of excitation wavelengths; and means for correlating the spectrum to a condition of the tissue sample.
means for exposing the tissue sample to an excitation radiation and thereby generating an emission radiation, said exposing means comprising a laser source outputting a beam;
means for synchronously scanning the wavelength of the excitation radiation and the wavelength of the emission radiation to produce a spectrum, said synchronous scanning means comprising means for directing the output beam of the laser source through a dye module having a plurality of dyes, and means for changing the dyes to achieve a range of excitation wavelengths; and means for correlating the spectrum to a condition of the tissue sample.
37. An apparatus for testing a tissue sample comprising:
means for exposing the tissue sample to an excitation radiation and thereby generating an emission radiation, said exposing means comprising a light source;
means for synchronously scanning the wavelength of the excitation radiation and the wavelength of the emission radiation to produce a spectrum, said synchronous scanning means including a first acousto-optic tunable filter having a variable input radio frequency selected to achieve a range of excitation wavelengths; and means for correlating the spectrum to a condition of the tissue sample.
means for exposing the tissue sample to an excitation radiation and thereby generating an emission radiation, said exposing means comprising a light source;
means for synchronously scanning the wavelength of the excitation radiation and the wavelength of the emission radiation to produce a spectrum, said synchronous scanning means including a first acousto-optic tunable filter having a variable input radio frequency selected to achieve a range of excitation wavelengths; and means for correlating the spectrum to a condition of the tissue sample.
38. An apparatus according to claim 37, wherein the synchronous scanning means further comprises a second acousto-optic tunable filter having a variable input radio frequency selected to achieve a range of emission wavelengths.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/300,202 US5599717A (en) | 1994-09-02 | 1994-09-02 | Advanced synchronous luminescence system |
US300,202 | 1994-09-02 | ||
PCT/US1995/011168 WO1996007889A1 (en) | 1994-09-02 | 1995-09-01 | Advanced synchronous luminescence system |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2230777A1 CA2230777A1 (en) | 1996-03-14 |
CA2230777C true CA2230777C (en) | 2003-03-18 |
Family
ID=23158129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002230777A Expired - Fee Related CA2230777C (en) | 1994-09-02 | 1995-09-01 | Advanced synchronous luminescence system |
Country Status (8)
Country | Link |
---|---|
US (2) | US5599717A (en) |
EP (1) | EP0778939A4 (en) |
KR (1) | KR100352689B1 (en) |
AU (1) | AU712172B2 (en) |
BR (1) | BR9508693A (en) |
CA (1) | CA2230777C (en) |
NZ (1) | NZ293404A (en) |
WO (1) | WO1996007889A1 (en) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5599717A (en) * | 1994-09-02 | 1997-02-04 | Martin Marietta Energy Systems, Inc. | Advanced synchronous luminescence system |
US5544268A (en) | 1994-09-09 | 1996-08-06 | Deacon Research | Display panel with electrically-controlled waveguide-routing |
US5735276A (en) * | 1995-03-21 | 1998-04-07 | Lemelson; Jerome | Method and apparatus for scanning and evaluating matter |
US6174424B1 (en) | 1995-11-20 | 2001-01-16 | Cirrex Corp. | Couplers for optical fibers |
US5953477A (en) * | 1995-11-20 | 1999-09-14 | Visionex, Inc. | Method and apparatus for improved fiber optic light management |
US6405069B1 (en) * | 1996-01-31 | 2002-06-11 | Board Of Regents, The University Of Texas System | Time-resolved optoacoustic method and system for noninvasive monitoring of glucose |
US6135965A (en) * | 1996-12-02 | 2000-10-24 | Board Of Regents, The University Of Texas System | Spectroscopic detection of cervical pre-cancer using radial basis function networks |
US6847490B1 (en) * | 1997-01-13 | 2005-01-25 | Medispectra, Inc. | Optical probe accessory device for use in vivo diagnostic procedures |
US6826422B1 (en) | 1997-01-13 | 2004-11-30 | Medispectra, Inc. | Spectral volume microprobe arrays |
US6631226B1 (en) * | 1997-01-27 | 2003-10-07 | Carl Zeiss Jena Gmbh | Laser scanning microscope |
US6344272B1 (en) * | 1997-03-12 | 2002-02-05 | Wm. Marsh Rice University | Metal nanoshells |
US6852252B2 (en) | 1997-03-12 | 2005-02-08 | William Marsh Rice University | Use of metalnanoshells to impede the photo-oxidation of conjugated polymer |
US6208783B1 (en) | 1997-03-13 | 2001-03-27 | Cirrex Corp. | Optical filtering device |
US6937885B1 (en) * | 1997-10-30 | 2005-08-30 | Hypermed, Inc. | Multispectral/hyperspectral medical instrument |
AU751456B2 (en) * | 1997-10-30 | 2002-08-15 | Hypermed Imaging, Inc. | Multispectral/hyperspectral medical instrument |
WO1999044045A1 (en) * | 1998-02-27 | 1999-09-02 | Massachusetts Institute Of Technology | Single molecule detection with surface-enhanced raman scattering and applications in dna or rna sequencing |
US6174291B1 (en) | 1998-03-09 | 2001-01-16 | Spectrascience, Inc. | Optical biopsy system and methods for tissue diagnosis |
US6428811B1 (en) | 1998-03-11 | 2002-08-06 | Wm. Marsh Rice University | Temperature-sensitive polymer/nanoshell composites for photothermally modulated drug delivery |
US6699724B1 (en) | 1998-03-11 | 2004-03-02 | Wm. Marsh Rice University | Metal nanoshells for biosensing applications |
US6728560B2 (en) | 1998-04-06 | 2004-04-27 | The General Hospital Corporation | Non-invasive tissue glucose level monitoring |
US6721582B2 (en) | 1999-04-06 | 2004-04-13 | Argose, Inc. | Non-invasive tissue glucose level monitoring |
US6505059B1 (en) | 1998-04-06 | 2003-01-07 | The General Hospital Corporation | Non-invasive tissue glucose level monitoring |
US7899518B2 (en) | 1998-04-06 | 2011-03-01 | Masimo Laboratories, Inc. | Non-invasive tissue glucose level monitoring |
US8024027B2 (en) | 1998-09-03 | 2011-09-20 | Hyperspectral Imaging, Inc. | Infrared endoscopic balloon probes |
US6741884B1 (en) | 1998-09-03 | 2004-05-25 | Hypermed, Inc. | Infrared endoscopic balloon probes |
WO2000037917A2 (en) | 1998-12-23 | 2000-06-29 | Medispectra, Inc. | Systems and methods for optical examination of samples |
CA2356195A1 (en) * | 1998-12-23 | 2000-06-29 | Medispectra, Inc. | Optical methods and systems for cervical screening |
SE9804551D0 (en) * | 1998-12-28 | 1998-12-28 | Amersham Pharm Biotech Ab | Arrangements useful for measurement and a measuring method that may utilize the arrangements |
US6404497B1 (en) * | 1999-01-25 | 2002-06-11 | Massachusetts Institute Of Technology | Polarized light scattering spectroscopy of tissue |
US6580935B1 (en) | 1999-03-12 | 2003-06-17 | Cirrex Corp. | Method and system for stabilizing reflected light |
JP2000262460A (en) * | 1999-03-18 | 2000-09-26 | Inst Of Physical & Chemical Res | Method for detecting specified location, method for biological measurement, device for detecting specified location of biological sample, and optical fiber holding device |
US20020132371A1 (en) * | 1999-09-27 | 2002-09-19 | Kreimer David I. | Amplification of analyte detection by substrates having particle structures with receptors |
US20040023293A1 (en) * | 1999-09-27 | 2004-02-05 | Kreimer David I. | Biochips for characterizing biological processes |
US20030232388A1 (en) * | 1999-09-27 | 2003-12-18 | Kreimer David I. | Beads having identifiable Raman markers |
WO2001033201A1 (en) * | 1999-11-03 | 2001-05-10 | Argose, Inc. | Asynchronous fluorescence scan |
US7187810B2 (en) * | 1999-12-15 | 2007-03-06 | Medispectra, Inc. | Methods and systems for correcting image misalignment |
US7260248B2 (en) * | 1999-12-15 | 2007-08-21 | Medispectra, Inc. | Image processing using measures of similarity |
US6902935B2 (en) * | 1999-12-15 | 2005-06-07 | Medispectra, Inc. | Methods of monitoring effects of chemical agents on a sample |
WO2001060247A1 (en) | 2000-02-18 | 2001-08-23 | Argose, Inc. | Generation of spatially-averaged excitation-emission map in heterogeneous tissue |
US7714301B2 (en) * | 2000-10-27 | 2010-05-11 | Molecular Devices, Inc. | Instrument excitation source and calibration method |
WO2002035260A2 (en) * | 2000-10-27 | 2002-05-02 | Molecular Devices Corporation | Light detection device |
US7354770B2 (en) | 2000-11-08 | 2008-04-08 | University Of North Florida | Sensing device and method using photo-induced charge movements |
US7892495B2 (en) * | 2000-11-08 | 2011-02-22 | Huebner Jay S | Sensing device and method for rapidly determining concentrations of microbial organisms using interfacial photo-voltages |
US8354647B2 (en) * | 2000-11-08 | 2013-01-15 | University Of North Florida | Photoelectric chemical sensor and sensing method utilizing interfacial photo-voltages |
US6839661B2 (en) * | 2000-12-15 | 2005-01-04 | Medispectra, Inc. | System for normalizing spectra |
US6707548B2 (en) | 2001-02-08 | 2004-03-16 | Array Bioscience Corporation | Systems and methods for filter based spectrographic analysis |
US6870613B1 (en) | 2001-03-07 | 2005-03-22 | Carolyn Tisone | Simultaneous recording of multispectral fluorescence signatures |
US20020151041A1 (en) * | 2001-03-15 | 2002-10-17 | Kreimer David I. | Enhancing surfaces for analyte detection |
AT410033B (en) * | 2001-06-06 | 2003-01-27 | Eurolab Instr Gmbh | METHOD AND MEASURING DEVICE FOR DETERMINING AT LEAST ONE LUMINESCENCE, FLOURENCE OR ABSORPTION PARAMETER OF A SAMPLE |
US6995841B2 (en) * | 2001-08-28 | 2006-02-07 | Rice University | Pulsed-multiline excitation for color-blind fluorescence detection |
US7057721B2 (en) * | 2002-01-10 | 2006-06-06 | Chemimage Corporation | Wide field method for detecting pathogenic microorganisms |
US6694799B2 (en) | 2002-02-22 | 2004-02-24 | Eastern Washington University | Method and apparatus for detection of particles |
US8131332B2 (en) * | 2002-04-04 | 2012-03-06 | Veralight, Inc. | Determination of a measure of a glycation end-product or disease state using tissue fluorescence of various sites |
CN1474175B (en) * | 2002-04-15 | 2010-05-26 | 黄鹰 | Super fine optical spectrum imaging instrument or system |
US6879398B2 (en) * | 2002-05-22 | 2005-04-12 | Lockheed Martin Corporation | Distributed contaminant optical monitoring system |
US7282723B2 (en) * | 2002-07-09 | 2007-10-16 | Medispectra, Inc. | Methods and apparatus for processing spectral data for use in tissue characterization |
US7136518B2 (en) * | 2003-04-18 | 2006-11-14 | Medispectra, Inc. | Methods and apparatus for displaying diagnostic data |
US7469160B2 (en) * | 2003-04-18 | 2008-12-23 | Banks Perry S | Methods and apparatus for evaluating image focus |
CA2491703A1 (en) * | 2002-07-09 | 2004-01-15 | Medispectra, Inc. | Methods and apparatus for characterization of tissue samples |
US20040208385A1 (en) * | 2003-04-18 | 2004-10-21 | Medispectra, Inc. | Methods and apparatus for visually enhancing images |
US6818903B2 (en) * | 2002-07-09 | 2004-11-16 | Medispectra, Inc. | Method and apparatus for identifying spectral artifacts |
US6933154B2 (en) * | 2002-07-09 | 2005-08-23 | Medispectra, Inc. | Optimal windows for obtaining optical data for characterization of tissue samples |
US20040208390A1 (en) * | 2003-04-18 | 2004-10-21 | Medispectra, Inc. | Methods and apparatus for processing image data for use in tissue characterization |
US20040209237A1 (en) * | 2003-04-18 | 2004-10-21 | Medispectra, Inc. | Methods and apparatus for characterization of tissue samples |
US6768918B2 (en) * | 2002-07-10 | 2004-07-27 | Medispectra, Inc. | Fluorescent fiberoptic probe for tissue health discrimination and method of use thereof |
WO2004031746A1 (en) * | 2002-10-02 | 2004-04-15 | Lumen Health Innovations, Inc. | Apparatus and methods relating to high speed spectroscopy and excitation-emission matrices |
CN100406872C (en) | 2002-11-04 | 2008-07-30 | 天津市先石光学技术有限公司 | Composite spectral measurement method and its spectral detection instrument |
US7192783B2 (en) * | 2003-02-05 | 2007-03-20 | Research Foundation Of The City University Of New York | Stokes shift emission spectroscopy for detection of disease and physiological state of specimen |
WO2005001431A2 (en) * | 2003-02-25 | 2005-01-06 | Ceyx Technologies, Inc. | Apparatus and method for chemical and biological agent sensing |
US7181219B2 (en) | 2003-05-22 | 2007-02-20 | Lucent Technologies Inc. | Wireless handover using anchor termination |
US7697975B2 (en) * | 2003-06-03 | 2010-04-13 | British Colombia Cancer Agency | Methods and apparatus for fluorescence imaging using multiple excitation-emission pairs and simultaneous multi-channel image detection |
US7103402B2 (en) * | 2003-10-02 | 2006-09-05 | Ut-Battelle, Llc | Advanced synchronous luminescence imaging for chemical and medical diagnostics |
US20050196826A1 (en) * | 2004-03-05 | 2005-09-08 | Sherrill James V. | Self calibrating detection |
FR2871358B1 (en) * | 2004-06-14 | 2007-02-09 | Mauna Kea Technologies Soc Par | METHOD AND SYSTEM FOR MICROSCOPIC MULTI-MARKING FIBER FLUORESCENCE IMAGING |
US20070037135A1 (en) * | 2005-08-08 | 2007-02-15 | Barnes Russell H | System and method for the identification and quantification of a biological sample suspended in a liquid |
US20070224694A1 (en) * | 2006-02-10 | 2007-09-27 | Puchalski Daniel M | Method and system for hyperspectral detection of animal diseases |
US20090155770A1 (en) * | 2007-12-12 | 2009-06-18 | Kimberly-Clark Worldwide, Inc. | Implantable devices for fiber optic based detection of nosocomial infection |
US8280471B2 (en) * | 2007-12-12 | 2012-10-02 | Kimberly-Clark Worldwide, Inc. | Fiber optic based detection of autofluorescent bacterial pathogens |
US8619257B2 (en) * | 2007-12-13 | 2013-12-31 | Kimberley-Clark Worldwide, Inc. | Recombinant bacteriophage for detection of nosocomial infection |
US8512975B2 (en) | 2008-07-24 | 2013-08-20 | Biomerieux, Inc. | Method for detection and characterization of a microorganism in a sample using time dependent spectroscopic measurements |
CN102272602B (en) * | 2008-10-31 | 2014-03-12 | 生物梅里埃公司 | Methods for isolation and identification of microorganisms |
BRPI0919896A2 (en) | 2008-10-31 | 2016-02-16 | Bio Merieux Inc | methods for the separation, characterization and / or identification of microorganisms by mass spectroscopy. |
CN102203588B (en) * | 2008-10-31 | 2015-03-18 | 生物梅里埃公司 | Methods for separation, characterization and/or identification of microorganisms using spectroscopy |
US8647835B2 (en) | 2008-10-31 | 2014-02-11 | BIO MéRIEUX, INC. | Methods for separation, characterization and/or identification of microorganisms using spectroscopy |
AU2009320332B2 (en) * | 2008-10-31 | 2014-07-31 | Biomerieux, Inc. | Methods for separation, characterization, and/or identification of microorganisms using raman spectroscopy |
US10167494B2 (en) * | 2008-10-31 | 2019-01-01 | Biomerieux, Inc. | Method for detection, characterization and/or identification of microorganisms in a sealed container |
CN102272601B (en) * | 2008-10-31 | 2014-09-17 | 生物梅里埃公司 | Methods for separation and characterization of microorganisms using identifier agents |
AU2009333848B2 (en) * | 2008-12-16 | 2016-02-18 | Biomerieux, Inc. | Methods for the characterization of microorganisms on solid or semi-solid media |
WO2010132749A2 (en) | 2009-05-15 | 2010-11-18 | Biomerieux, Inc. | Automated transfer mechanism for microbial. detection apparatus |
US9574219B2 (en) * | 2009-05-15 | 2017-02-21 | Biomerieux, Inc. | Device for sampling a specimen container |
DE102010015915A1 (en) * | 2010-03-11 | 2011-09-15 | Leica Microsystems Cms Gmbh | Method for an accelerated excitation wavelength scan in a fluorescence microscope |
US10156479B2 (en) * | 2011-05-09 | 2018-12-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Spatial-domain low-coherence quantitative phase microscopy |
CN105606577B (en) * | 2011-06-24 | 2019-08-13 | 贝克顿·迪金森公司 | Absorption spectrum scans flow cytometry |
CN102353451A (en) * | 2011-09-16 | 2012-02-15 | 长春理工大学 | Secondary acousto-optic tunable filter hyperspectral imaging method and device |
WO2015019327A1 (en) * | 2013-08-09 | 2015-02-12 | University Of Calcutta | Systems and methods for liquid quality assessment |
DE102013227103B4 (en) * | 2013-09-03 | 2018-05-30 | Leica Microsystems Cms Gmbh | Microscope with an acousto-optic device |
US9927363B2 (en) * | 2015-03-24 | 2018-03-27 | Arizona Board Of Regents On Behalf Of Arizona State University | Real-time baseline correction technique for infrared time-resolved photoluminescence |
US11506598B2 (en) | 2019-11-29 | 2022-11-22 | Epir, Inc. | Compact apparatus for high-speed chemical spectral signature measurement and method of using same |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3734621A (en) * | 1971-12-06 | 1973-05-22 | Hewlett Packard Co | Spectrophotometer utilizing memory storage calibration techniques |
US4930516B1 (en) * | 1985-11-13 | 1998-08-04 | Laser Diagnostic Instr Inc | Method for detecting cancerous tissue using visible native luminescence |
US5042494A (en) * | 1985-11-13 | 1991-08-27 | Alfano Robert R | Method and apparatus for detecting cancerous tissue using luminescence excitation spectra |
US5131398A (en) * | 1990-01-22 | 1992-07-21 | Mediscience Technology Corp. | Method and apparatus for distinguishing cancerous tissue from benign tumor tissue, benign tissue or normal tissue using native fluorescence |
US5261410A (en) * | 1991-02-07 | 1993-11-16 | Alfano Robert R | Method for determining if a tissue is a malignant tumor tissue, a benign tumor tissue, or a normal or benign tissue using Raman spectroscopy |
US5303026A (en) * | 1991-02-26 | 1994-04-12 | The Regents Of The University Of California Los Alamos National Laboratory | Apparatus and method for spectroscopic analysis of scattering media |
US5293872A (en) * | 1991-04-03 | 1994-03-15 | Alfano Robert R | Method for distinguishing between calcified atherosclerotic tissue and fibrous atherosclerotic tissue or normal cardiovascular tissue using Raman spectroscopy |
US5377003A (en) * | 1992-03-06 | 1994-12-27 | The United States Of America As Represented By The Department Of Health And Human Services | Spectroscopic imaging device employing imaging quality spectral filters |
US5306403A (en) * | 1992-08-24 | 1994-04-26 | Martin Marietta Energy Systems, Inc. | Raman-based system for DNA sequencing-mapping and other separations |
US5272089A (en) * | 1992-09-01 | 1993-12-21 | Martin Marietta Energy Systems, Inc. | Enhanced photo-activated luminescence for screening polychlorobiphenyls (PCBs) and other related chlorinated compounds |
US5599717A (en) * | 1994-09-02 | 1997-02-04 | Martin Marietta Energy Systems, Inc. | Advanced synchronous luminescence system |
-
1994
- 1994-09-02 US US08/300,202 patent/US5599717A/en not_active Expired - Lifetime
-
1995
- 1995-09-01 KR KR1019970701382A patent/KR100352689B1/en not_active IP Right Cessation
- 1995-09-01 BR BR9508693A patent/BR9508693A/en not_active Application Discontinuation
- 1995-09-01 AU AU35833/95A patent/AU712172B2/en not_active Ceased
- 1995-09-01 CA CA002230777A patent/CA2230777C/en not_active Expired - Fee Related
- 1995-09-01 WO PCT/US1995/011168 patent/WO1996007889A1/en not_active Application Discontinuation
- 1995-09-01 EP EP95933028A patent/EP0778939A4/en not_active Withdrawn
- 1995-09-01 NZ NZ293404A patent/NZ293404A/en unknown
-
1996
- 1996-12-03 US US08/760,165 patent/US5938617A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU3583395A (en) | 1996-03-27 |
US5599717A (en) | 1997-02-04 |
EP0778939A1 (en) | 1997-06-18 |
NZ293404A (en) | 1998-11-25 |
US5938617A (en) | 1999-08-17 |
KR100352689B1 (en) | 2002-12-28 |
WO1996007889A1 (en) | 1996-03-14 |
AU712172B2 (en) | 1999-10-28 |
KR970705748A (en) | 1997-10-09 |
CA2230777A1 (en) | 1996-03-14 |
EP0778939A4 (en) | 1999-09-01 |
BR9508693A (en) | 1998-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2230777C (en) | Advanced synchronous luminescence system | |
Vo-Dinh | A hyperspectral imaging system for in vivo optical diagnostics | |
JP3752693B2 (en) | Laser-induced differential normalization fluorescence cancer diagnosis method and apparatus | |
US7103402B2 (en) | Advanced synchronous luminescence imaging for chemical and medical diagnostics | |
US5303026A (en) | Apparatus and method for spectroscopic analysis of scattering media | |
US6069689A (en) | Apparatus and methods relating to optical systems for diagnosis of skin diseases | |
US5713364A (en) | Spectral volume microprobe analysis of materials | |
US5813987A (en) | Spectral volume microprobe for analysis of materials | |
US6104945A (en) | Spectral volume microprobe arrays | |
US5293872A (en) | Method for distinguishing between calcified atherosclerotic tissue and fibrous atherosclerotic tissue or normal cardiovascular tissue using Raman spectroscopy | |
US5687730A (en) | Apparatus for detecting the presence of abnormal tissue within a target tissue beneath the skin of a patient | |
US7202947B2 (en) | Depth-resolved fluorescence instrument with angled excitation | |
WO2004046696A1 (en) | Composite spectral measurement method and its spectral detection instrument | |
CA2228308A1 (en) | Optical microprobes and methods for spectral analysis of materials | |
af Klinteberg et al. | Compact medical fluorosensor for minimally invasive tissue characterization | |
US11555742B2 (en) | Image guided micro-Raman spectroscopy | |
JP2520665B2 (en) | Fluorescence microspectrometer | |
CN111281313A (en) | On-line focus detection system based on Raman spectrum | |
Brandt et al. | Laser Raman spectrometer for the studies of biomolecules with monitoring temperature of the samples | |
Colasanti et al. | Noninvasive spectroscopic analysis of dermatological lesions excited with N2 laser | |
JPH11118716A (en) | Method and apparatus for optical inspection | |
WO2021011823A1 (en) | Digital mirror device based code-division multiplexed raman optical mapping system for wide field imaging | |
Zelenchuk et al. | Remote sensing as a method of cervical cancer diagnosis | |
JPH05111494A (en) | Measuring instrument |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |